Viridian Therapeutics, Inc. — 2023 Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended December 31, 2023; the filing does not provide standalone fourth-quarter financial results in the supplied text. Viridian is a clinical-stage biopharmaceutical company with no products approved for sale. Its lead program is VRDN-001, an intravenous IGF-1R antibody in Phase 3 trials for active and chronic thyroid eye disease (TED). The company is also advancing subcutaneous VRDN-003 for TED and preclinical FcRn inhibitors VRDN-006 and VRDN-008.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0.3 million | $1.8 million |
| Research and development expense | $159.8 million | $100.9 million |
| General and administrative expense | $95.0 million | $35.2 million |
| Operating loss | $254.5 million | $134.3 million |
| Net loss | $237.7 million | $129.9 million |
| Net loss per share, basic and diluted | $5.31 | $4.05 |
| Net cash used in operating activities | $184.2 million | $93.8 million |
Revenue came from the Zenas BioPharma collaboration, not product sales. Product gross margins are not applicable because Viridian has no approved commercial products. Cash and cash equivalents were $102.8 million and short-term investments were $374.5 million at year-end, totaling $477.4 million. Total liabilities were $48.4 million; long-term debt, net, was $20.2 million, with $20.0 million of gross loan principal outstanding. The Hercules loan bears interest at 8.95% at year-end, is secured by substantially all company assets except intellectual property, and matures October 1, 2026.
2023 cash flows included $94.3 million used in investing activities, primarily net purchases of investments, and $225.7 million provided by financing activities. Cash and cash equivalents declined by $52.8 million during the year. The company reported an accumulated deficit of $725.9 million and stockholders’ equity of $442.0 million.
Changes versus the prior comparable period
- Net loss increased by $107.9 million year over year. R&D expense rose $58.9 million, mainly from Phase 3 trial costs, personnel, licensing and development fees, and manufacturing activities.
- G&A expense rose $59.8 million. The increase included $31.0 million of severance costs related primarily to former executive officers, including $26.1 million of incremental share-based compensation from option modifications and accelerated vesting.
- Revenue decreased $1.5 million, primarily because of the timing of Zenas collaboration activities; 2022 included a $1.0 million development milestone.
- Other income, net increased to $16.7 million from $4.4 million, primarily reflecting higher interest income on investments.
- Financing included approximately $186.0 million gross proceeds from the 2023 private placement, ATM sales, and $15.0 million drawn under the amended Hercules facility. In January 2024, the company raised a further approximately $186.3 million gross from ATM and underwritten common-stock sales.
Outlook, management commentary, risks, and unusual items
- Management expects available resources, including January 2024 equity proceeds, to fund planned operations into the second half of 2026. The company nevertheless expects continued losses and says it will require additional capital over time; runway depends on development costs, trial timing, and other assumptions.
- Management expected topline VRDN-001 THRIVE results in mid-2024 and THRIVE-2 results by year-end 2024. It planned to begin a global pivotal VRDN-003 program in mid-2024, subject to regulatory alignment. These are forward-looking expectations, not reported outcomes.
- Management planned to submit an IND for VRDN-006 by year-end 2024 and expected healthy-volunteer data in the second half of 2025. VRDN-008 remained in preclinical development.
- VRDN-001 Phase 1/2 results were encouraging but based on small cohorts: active TED included 21 treated patients and chronic TED 12. The Phase 3 trials will determine whether these results translate into pivotal-trial efficacy and safety.
- Key risks include clinical failure or delay, regulatory requirements and safety findings, competition in TED and autoimmune disease, and dependence on third parties for trials and manufacturing. Viridian relied on WuXi for clinical materials, had no redundant supply arrangement, and disclosed plans to move certain activities outside WuXi’s Chinese facilities. It also reported known GCP documentation deficiencies at clinical sites and ongoing remediation efforts.
- Related-party relationships warrant attention: the Zenas collaboration and Paragon license arrangements were identified as related-party transactions. Paragon-related R&D costs were $12.0 million in 2023. The company also disclosed future potential milestone and royalty obligations under licensing and device-development agreements.
- The filing reports no legal proceedings believed to have a material adverse effect. Management and the auditor concluded internal control over financial reporting was effective as of year-end; the financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Whether THRIVE and THRIVE-2 results, safety data, and regulatory feedback support the proposed VRDN-001 registration strategy.
- Whether VRDN-003 pivotal trial plans and dosing intervals are confirmed by regulators and supported by clinical evidence, rather than pharmacokinetic modeling alone.
- Whether the stated cash runway remains valid after trial spending, manufacturing costs, and any additional financing; also assess dilution from common and convertible preferred stock issuances.
- The status of the Hercules debt, any milestone-dependent borrowing availability, interest and repayment terms, and the effect of its asset liens and covenants.
- Progress in diversifying manufacturing and remediating clinical-site GCP documentation issues, including any consequences for trial data or timelines.
- The terms and governance of related-party arrangements and the potential cash burden of future license milestones, commercial milestones, and royalties.